跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Can AI Discover New Drugs? A High-Level Overview

1Why Drug Discovery Is Hard, and Where AI Fits2How AI Learns From Molecules and Proteins3Finding and Validating a Biological Target4Designing Molecules: Generative AI and Virtual Screening5From Hit to Lead: Optimizing Properties With AI6What AI Still Cannot Do7Judging the Claims: Real Successes, Failures, and Open Questions
Judging the Claims: Real Successes, Failures, and Open Questions

Sorting Claims by What They Actually Show

1 / 4
Before you sort anything, notice what each card is really claiming. A card that says a model generated a molecule with a strong predicted binding score is sitting on the bottom rung — nothing has been made, nothing has been measured. A card that says the compound was synthesized and showed activity in a cell assay has climbed one rung, but it still tells you nothing about whether it will survive in a living body. The deciding question is almost always the same: what was measured, and against what? If a card reports a result with no comparison — no existing drug, no conventionally designed molecule — treat it as a description rather than evidence of improvement. And watch for cards that praise the method while quietly avoiding the outcome; those are the ones that usually belong in the overstated bin.
0:00 / 0:00

Every claim about an AI-discovered drug can be placed on a ladder of evidence, and its weight is set by the rung it occupies rather than by the sophistication of the method behind it. The lowest rung is a computational prediction: a model proposes a molecule or a binding score, and nothing has been made or measured. The next rung is a synthesized compound tested in a laboratory assay, which establishes that the molecule does something measurable in a defined system. Above that sits testing in animals, where absorption, metabolism, and toxicity begin to appear as real obstacles rather than predictions. The fourth rung is a human trial designed primarily for safety and tolerability in a small number of participants. Only the top rung — a controlled human trial measuring whether patients actually benefit — supports the claim that a drug works.

A practical checklist follows from this ladder. First, what was measured, and in what system? Second, what was it compared against — an existing treatment, a conventionally designed molecule, or nothing? Third, how far up the ladder has the program actually climbed, as opposed to how far the announcement implies? Fourth, is the emphasis on the method used or on the outcome achieved? Fifth, what is missing: the number of failed candidates, the elapsed time, the presence of a control group, peer review?

Sorting a claim is not a judgment about whether the science is good. A well-executed computational study can be excellent science and still be weak evidence that a drug will work, because those are different questions.

上一页1 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion